Passage BIO Announces Board and Executive Changes
Ticker: PASG · Form: 8-K · Filed: Sep 18, 2025 · CIK: 1787297
| Field | Detail |
|---|---|
| Company | Passage Bio, Inc. (PASG) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
TL;DR
Passage BIO shakes up its board and exec pay structure.
AI Summary
Passage BIO, Inc. announced on September 16, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain officers and directors, along with the election of new directors and adjustments to compensatory arrangements for its key executives.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, potentially impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty about future strategy and execution.
Key Numbers
- 001-39231 — SEC File Number (Identifies the company's filing history with the SEC.)
- 82-2729751 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Passage BIO, Inc. (company) — Registrant
- September 16, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Philadelphia, PA (location) — Principal executive offices address
FAQ
What specific roles did the departing officers and directors hold?
The filing indicates the departure of 'certain officers' and 'certain directors' but does not specify their individual roles or names in this section.
Who are the newly elected directors?
The filing mentions the election of new directors but does not provide their names or any biographical information in this excerpt.
What are the details of the compensatory arrangements for the officers?
The filing notes 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not provided in this initial summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing occurred on September 16, 2025.
What is Passage BIO, Inc.'s primary business sector?
Passage BIO, Inc. is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' sector, with SIC code 2836.
Filing Stats: 492 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-09-18 16:30:34
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share PASG The Nasdaq S
Filing Documents
- tm2526408d1_8k.htm (8-K) — 26KB
- 0001104659-25-091288.txt ( ) — 189KB
- pasg-20250916.xsd (EX-101.SCH) — 3KB
- pasg-20250916_lab.xml (EX-101.LAB) — 33KB
- pasg-20250916_pre.xml (EX-101.PRE) — 22KB
- tm2526408d1_8k_htm.xml (XML) — 4KB
02 Departure of Director or Certain
Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 16, 2025, Saqib Islam notified Passage Bio, Inc. (the " Company ") of his decision to resign from the Company's Board of Directors (the " Board "), including from the Audit Committee of the Board (the " Audit Committee "), effective immediately (the " Resignation Date "). Mr. Islam's decision was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. In connection with Mr. Islam's resignation, the Board appointed Athena Countouriotis, M.D., as a member of the Audit Committee to fill the vacancy left by Mr. Islam, and reduced the size of the Board from eight to seven members, effective as of the Resignation Date. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PASSAGE BIO, INC. Date: September 18, 2025 By: /s/ Kathleen Borthwick Kathleen Borthwick Chief Financial Officer